← All entries

Huperzine A: galantamine's cousin, without the payoff

cholinergic

Huperzine A hits the same enzyme galantamine does, acetylcholinesterase, at roughly double the half-life. The pharmacological rationale is clean: if galantamine sharpens dreams through cholinergic potentiation, huperzine should land in the same place. I ran it at 200 to 400 mcg on a wake-back-to-bed schedule to find out.

In practice it underdelivered. Recall nudged up only modestly, lucidity barely registered, and the long half-life, somewhere around 10 to 14 hours, meant the effect bled into the following night and muddied the protocol. Several mornings came with a headache on waking. On the nights I paired it with blue lotus there was no additive effect.

So it lands where a lot of plausible compounds land: a sound hypothesis still waiting on real data. The dream-specific evidence is anecdotal, there is no controlled trial, and the slow clearance makes it harder to run cleanly than galantamine. For now it stays a low-signal cholinergic, interesting mostly for the contrast it draws with the one that actually worked.

Not medical advice. Nightcone documents self-experimentation for research interest only. Nothing here is a recommendation to ingest any substance.

Nightcone Labs Dispatch

Results from controlled oneirogen experiments. What impacted dreaming, what didn't, and topical news. New tests each cycle.